|
Mar 3
|
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 26
|
Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 25
|
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
|
|
Feb 24
|
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
|
|
Feb 13
|
MediWound commences Phase III trial for venous leg ulcers treatment
|
|
Feb 12
|
MediWound Launches Phase III Trial Evaluating EscharEx for Treating Venous Leg Ulcers
|
|
Feb 12
|
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
|
|
Jul 30
|
MediWound reinforces wound therapy EscharEx data ahead of Phase III trial
|
|
Jul 29
|
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
|
|
May 13
|
Investors in MediWound (NASDAQ:MDWD) have seen decent returns of 65% over the past year
|
|
Apr 25
|
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
|
|
Apr 17
|
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
|
|
Mar 25
|
Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
|
|
Mar 25
|
What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
|
|
Mar 24
|
MediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
|
|
Mar 21
|
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 21
|
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
|
|
Mar 14
|
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 7
|
Retail investors who hold 38% of MediWound Ltd. (NASDAQ:MDWD) gained 15%, institutions profited as well
|
|
Mar 6
|
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
|